Genistein Effects on Quantitative Ultrasound Parameters and Bone Mineral Density in Osteopenic Postmenopausal Women

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2009 Feb 25

PMID 19238303

Citations 16

Authors

M Atteritano

S Mazzaferro

A Frisina

M L Cannata

A Bitto

R DAnna

F Squadrito

I Macri

N Frisina

M Buemi

Affiliations

Soon will be listed here.

Abstract

Unlabelled: This study aimed at evaluating the effects of genistein (54 mg/die) on calcaneus and phalanges ultrasound (QUS) parameters and bone mineral density in osteopenic postmenopausal women. We concluded that genistein prevented bone loss in the osteopenic postmenopausal women and improves QUS parameters at the calcaneus and phalanges.

Introduction: The purpose of the study was to evaluate the effects of genistein (54 mg/die) on quantitative ultrasound (QUS) parameters of the calcaneus and hand phalange and on bone mineral density (BMD) in osteopenic postmenopausal women.

Methods: One hundred thirty-eight women (age 49-67 years) were assigned to receive genistein or placebo. Bone status was assessed by measuring the anteroposterior lumbar spine and femoral neck BMD by dual energy X-ray absorptiometry and by ultrasound of the calcaneus (Achilles Plus, GE, Lunar) and of the phalanges (Bone Profiler. IGEA) at baseline and after a 1- and 2-year treatment.

Results: At the end of the experimental period, genistein had significantly increased BMD in the femur and lumbar spine (p < 0.001). The stiffness index, amplitude-dependent speed of sound, and bone transmission time in the genistein group had increased significantly at the end of study (+5.3, p < 0.001; +3.6%, p < 0.001; +4.6, p < 0.001, respectively).

Conclusions: This study confirms that genistein prevented bone loss in the osteopenic postmenopausal women and it improves the QUS parameters.

Citing Articles

A review on therapeutic mechanism of medicinal plants against osteoporosis: effects of phytoconstituents.

Kumari S, Singh M, Nupur , Jain S, Verma N, Malik S Mol Biol Rep. 2023; 50(11):9453-9468.

PMID: 37676432 DOI: 10.1007/s11033-023-08751-4.

Heel quantitative ultrasound (QUS) predicts incident fractures independently of trabecular bone score (TBS), bone mineral density (BMD), and FRAX: the OsteoLaus Study.

Metrailler A, Hans D, Lamy O, Rodriguez E, Shevroja E Osteoporos Int. 2023; 34(8):1401-1409.

PMID: 37154943 PMC: 10382398. DOI: 10.1007/s00198-023-06728-4.

Activating Wnt/β-catenin signaling by autophagic degradation of APC contributes to the osteoblast differentiation effect of soy isoflavone on osteoporotic mesenchymal stem cells.

Ge J, Yu Y, Li J, Li M, Xia S, Xue K Acta Pharmacol Sin. 2023; 44(9):1841-1855.

PMID: 36973541 PMC: 10462682. DOI: 10.1038/s41401-023-01066-x.

Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients.

Kaneko K, Chen H, Kaufman M, Sverdlov I, Stein E, Park-Min K Clin Transl Med. 2021; 11(10):e526.

PMID: 34709753 PMC: 8506634. DOI: 10.1002/ctm2.526.

Botanicals in Postmenopausal Osteoporosis.

Slupski W, Jawien P, Nowak B Nutrients. 2021; 13(5).

PMID: 34064936 PMC: 8151026. DOI: 10.3390/nu13051609.

References

Gonnelli S, Cepollaro C, Montagnani A, Martini S, Gennari L, Mangeri M . Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. Osteoporos Int. 2002; 13(5):415-21. DOI: 10.1007/s001980200048. View

Marin F, Lopez-Bastida J, Diez-Perez A, Sacristan J . Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis. Calcif Tissue Int. 2004; 74(3):277-83. DOI: 10.1007/s00223-003-0135-0. View

Lenora J, Gerdhem P, Obrant K, Ivaska K . Bone turnover markers are correlated with quantitative ultrasound of the calcaneus: 5-year longitudinal data. Osteoporos Int. 2008; 20(7):1225-32. DOI: 10.1007/s00198-008-0769-x. View

Yanagihara K, Ito A, Toge T, Numoto M . Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res. 1993; 53(23):5815-21. View

Castelo-Branco C, Figueras F, Sanjuan A, Pons F, Vicente J, Vanrell J . Long-term postmenopausal hormone replacement therapy effects on bone mass: differences between surgical and spontaneous patients. Eur J Obstet Gynecol Reprod Biol. 1999; 83(2):207-11. DOI: 10.1016/s0301-2115(98)00313-3. View

Scharbo-Dehaan M . Hormone replacement therapy. Nurse Pract. 1996; 21(12 Pt 2):1-13; quiz 14-5. DOI: 10.1097/00006205-199612001-00001. View

Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M . Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med. 2007; 146(12):839-47. DOI: 10.7326/0003-4819-146-12-200706190-00005. View

Messina M, Ho S, Alekel D . Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care. 2004; 7(6):649-58. DOI: 10.1097/00075197-200411000-00010. View

Ingle B, Machado A, Pereda C, Eastell R . Monitoring alendronate and estradiol therapy with quantitative ultrasound and bone mineral density. J Clin Densitom. 2005; 8(3):278-86. DOI: 10.1385/jcd:8:3:278. View

10.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

11.

Recker R . Clinical review 41: Current therapy for osteoporosis. J Clin Endocrinol Metab. 1993; 76(1):14-6. DOI: 10.1210/jcem.76.1.8421079. View

12.

Bingham S, Atkinson C, Liggins J, Bluck L, Coward A . Phyto-oestrogens: where are we now?. Br J Nutr. 1998; 79(5):393-406. DOI: 10.1079/bjn19980068. View

13.

Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo E, Marini R . Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. J Clin Endocrinol Metab. 2004; 89(1):188-92. DOI: 10.1210/jc.2003-030891. View

14.

Beral V . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362(9382):419-27. DOI: 10.1016/s0140-6736(03)14065-2. View

15.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

16.

Sha G, Lin S . Genistein inhibits proliferation of human endometrial endothelial cell in vitro. Chin Med Sci J. 2008; 23(1):49-53. DOI: 10.1016/s1001-9294(09)60010-9. View

17.

Horiuchi T, Onouchi T, Takahashi M, Ito H, Orimo H . Effect of soy protein on bone metabolism in postmenopausal Japanese women. Osteoporos Int. 2000; 11(8):721-4. DOI: 10.1007/s001980070072. View

18.

Gluer C, Hans D . How to use ultrasound for risk assessment: a need for defining strategies. Osteoporos Int. 1999; 9(3):193-5. DOI: 10.1007/s001980050135. View

19.

. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1999; 350(9084):1047-59. View

20.

Krieg M, Barkmann R, Gonnelli S, Stewart A, Bauer D, Del Rio Barquero L . Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom. 2008; 11(1):163-87. DOI: 10.1016/j.jocd.2007.12.011. View